Aging-Related Tau Astrogliopathy (ARTAG) is a neuropathological entity characterized by tau-positive astrocytic lesions in the aging brain. First described in 2015, ARTAG represents a distinct pattern of age-related tau pathology primarily affecting astrocytes rather than neurons. This condition has gained increasing recognition as a contributor to cognitive decline in the aging population and as a potential comorbid pathology in various neurodegenerative diseases.
- Full Name: Aging-Related Tau Astrogliopathy
- Abbreviation: ARTAG
- Classification: Neurodegeneration / Tauopathy / Astrogliopathy
- ICD-10 Code: G31.9 (Unspecified degenerative disease of nervous system)
ARTAG is commonly observed in the aging population:
- Prevalence: Found in approximately 10-20% of cognitively normal elderly individuals
- Age: Primarily affects individuals over 70 years of age
- Risk factors: Advanced age is the primary risk factor
Autopsy-based studies have revealed:
- Community-based cohorts show ARTAG prevalence of 12-18% in individuals over 80 years
- ARTAG is more common in individuals without significant cognitive impairment
- There appears to be no strong gender predilection
The clinical significance of ARTAG remains an area of active investigation:
- Often found incidentally at autopsy in cognitively normal individuals
- May contribute to subtle cognitive impairment in some cases
- Frequently coexists with other neurodegenerative pathologies
- The impact on cognition appears to be modulated by comorbid pathologies
ARTAG commonly co-occurs with:
ARTAG is characterized by two main lesion types:
- Thorn-shaped astrocytes (TSAs): Triangular or thorn-shaped astrocytic processes extending from the cell body, typically oriented perpendicular to the pial surface
- Epidermoid tufted astrocytes: Tufted processes extending from astrocytic cell bodies, often forming dense perivascular arrangements
Lesions typically involve:
- Gray matter: Superficial cortical layers (Layer 1-3), particularly in the frontal and temporal lobes
- White matter: Subcortical and periventricular regions
- Subpial region: Along the brain surface
- Perivascular regions: Around small blood vessels
ARTAG shows regional variation:
- Common locations: Frontal cortex, temporal cortex, hippocampus
- Less common: Occipital cortex, parietal cortex, cerebellum
- White matter: Often involves frontal white matter
ARTAG can be classified by anatomical distribution:
- Cortical: Primarily gray matter involvement
- Subpial: Predominant involvement of the subpial layer
- White matter: Predominant white matter involvement
- Mixed: Combined patterns
The mechanisms underlying tau accumulation in astrocytes differ from neuronal tauopathy:
- Tau isoform composition: ARTAG lesions predominantly contain 4-repeat (4R) tau, similar to other tauopathies
- Astrocyte-specific vulnerability: Astrocytes may have unique mechanisms for tau uptake, aggregation, and clearance
- Propagation hypothesis: Tau may propagate from neurons to astrocytes via extracellular vesicles or direct transfer
ARTAG is associated with astrocytic dysfunction:
- Reactive astrogliosis: ARTAG astrocytes show signs of activation
- Impaired potassium buffering: Affected astrocytes may have reduced capacity for potassium homeostasis
- ** glutamate transport**: Dysfunction may affect glutamate clearance
- Blood-brain barrier interactions: Astrocyte end-feet may be affected
Key molecular pathways implicated in ARTAG:
- Cell cycle re-entry: Some evidence suggests astrocytic cell cycle abnormalities
- Oxidative stress: Accumulation of oxidative damage
- Mitochondrial dysfunction: Impaired energy metabolism
- Autophagy-lysosomal pathway: Reduced clearance of tau aggregates
- Neuroinflammation: Interaction with microglial activation
ARTAG shares features with other 4R tauopathies:
| Tauopathy |
Neuronal Tau |
Astrocytic Tau |
Key Features |
| ARTAG |
Variable |
Prominent |
Age-related, often incidental |
| PSP |
Moderate |
Moderate |
Brainstem predominant |
| CBD |
Moderate |
Moderate |
Cortical-subcortical |
| AGD |
Variable |
Moderate |
Argyrophilic grains |
ARTAG is related to but distinct from PART:
- PART primarily involves neuronal tau pathology
- ARTAG has prominent astrocytic involvement
- Both are age-related but have different anatomical distributions
While antemortem diagnosis is challenging:
- MRI: May show subtle white matter changes but is not specific for ARTAG
- PET: Tau PET ligands may show limited uptake in ARTAG regions
- Emerging techniques: Astrocyte-specific PET ligands are under development
Definitive diagnosis requires neuropathological examination:
- Immunohistochemistry: Phosphorylated tau antibodies (AT8, AT100, PHF-1)
- Regional sampling: Multiple brain regions must be examined
- Differential staining: Distinguishing from other astrocytic pathologies
ARTAG must be distinguished from:
- Astrocytic tau pathology in PSP: Different distribution pattern
- Astrocytic plaques in CBD: Distinct morphology
- Age-related tau astrogliopathy: Same entity
- Secondary tauopathy: Due to other underlying conditions
Animal models of ARTAG are limited but emerging:
- Transgenic models: Some mouse models show astrocytic tau accumulation
- Viral vector models: AAV-mediated tau expression in astrocytes
- Age-related models: Natural aging studies in rodents
Current models have challenges:
- Limited recapitulation of human ARTAG morphology
- Difficulty in modeling age-related processes
- Species differences in astrocyte biology
Currently no validated ARTAG-specific biomarkers:
- CSF tau: Total and phosphorylated tau may be elevated but not specific
- Blood biomarkers: Under investigation but not validated
- Neurofilament light chain: May indicate neurodegeneration
Emerging approaches include:
- Tau PET: Current ligands have limited astrocyte specificity
- Astrocyte PET: Novel ligands targeting astrocyte markers in development
- MRI: Advanced techniques may detect microstructural changes
No ARTAG-specific treatments exist:
- Disease-modifying therapies for ARTAG have not been developed
- Most therapeutic approaches target neuronal tau pathology
- The impact of reducing astrocytic tau on clinical outcomes is unclear
Several approaches are theoretically applicable:
- Anti-tau antibodies: May reduce extracellular tau propagation
- Small molecule tau inhibitors: Could affect aggregation
- Astrocyte-modulating therapies: Targeting astrocyte dysfunction
- Anti-inflammatory treatments: Addressing neuroinflammation
Management focuses on:
- Symptomatic treatment: Addressing cognitive and motor symptoms
- Comorbidity management: Treating co-occurring pathologies
- Supportive care: Quality of life optimization
Current research priorities include:
- Epidemiological studies: Defining true prevalence and clinical impact
- Mechanistic studies: Understanding astrocyte-specific tau biology
- Biomarker development: Identifying antemortem diagnostic markers
- Therapeutic development: Targeting astrocytic tau pathology
- ARTAG working groups have been established
- Standardized diagnostic criteria are being refined
- Multi-center studies are examining prevalence and clinical correlations
The immunohistochemical profile of ARTAG is distinctive:
- Phosphorylated tau antibodies: AT8 (PHF-tau, Ser202/Thr205), AT100 (Thr212/Ser214), and PHF-1 (Ser396/404) show strong labeling
- 3R vs 4R tau: Predominance of 4R tau isoform, similar to PSP and CBD
- Tau-5: Pan-tau antibody shows less intense staining
- 3-repeat tau: Variable, often sparse staining
Electron microscopy studies reveal:
- Straight filaments: Predominant filament type in ARTAG
- Paired helical filaments: Less common compared to AD
- Granular osmiophilic deposits: Occasionally observed
- Astrocytic processes: Accumulation of tau within astrocytic cytoplasm
Biochemical studies of ARTAG tissue show:
- Tau aggregates: Sarkosyl-insoluble tau fractions
- Phosphorylation pattern: Distinct phosphorylation sites compared to AD
- Truncation patterns: Unique C-terminal fragments
- Oligomeric tau: Presence of soluble tau oligomers
Patients with ARTAG may exhibit:
- Mild cognitive impairment: Often subdomain-specific
- Executive dysfunction: Particularly common
- Memory complaints: Variable, often less prominent than in AD
- Processing speed deficits: Common in formal testing
- Attention deficits: Particularly for complex tasks
While not primarily a movement disorder, ARTAG may be associated with:
- Gait disturbance: Often attributed to comorbid pathologies
- Parkinsonism: When co-occurring with other tauopathies
- Balance problems: Related to white matter involvement
- Subtle motor signs: May be detected on detailed examination
Behavioral changes reported include:
- Apathy: Common finding
- Depression: Frequently observed
- Anxiety: Less commonly reported
- Irritability: May occur in some patients
¶ Age of Onset and Disease Duration
- Typical age: 70-85 years at death
- Disease duration: Difficult to determine due to often incidental finding
- Progression: Likely slowly progressive if pure ARTAG
While primarily sporadic, genetic factors may influence ARTAG:
- MAPT haplotypes: H1 haplotype may increase risk
- APOE genotype: APOE ε4 may increase comorbidity with AD
- Genome-wide associations: Ongoing studies identify potential risk loci
Proposed risk factors include:
- Cardiovascular disease: May contribute to pathology
- Diabetes: Potential risk factor
- Traumatic brain injury: Possible association
- Educational attainment: Lower education may be risk factor
Potential protective factors include:
- Physical activity: May reduce risk
- Cognitive reserve: Higher education may modify impact
- Mediterranean diet: Associated with reduced neurodegeneration
The MAPT gene on chromosome 17q21.31 is central to tauopathies:
- H1 haplotype: Major risk factor for PSP and potentially ARTAG
- Subhaplotypes: H1c associated with specific pathologies
- Mutations: Some MAPT mutations cause familial tauopathies
Genome-wide studies have identified:
- STX6: Syntaxin-6, involved in vesicle trafficking
- EIF2AK3: Endoplasmic reticulum stress response
- NFASC: Neurofascin, cell adhesion molecule
- PERK pathway genes: Involved in protein folding response
- International prevalence: Similar rates across studies from different countries
- Population studies: Multi-ethnic cohorts show comparable rates
- Autopsy series: Consistent findings across academic centers
| Age Group |
Prevalence |
| 60-69 years |
5-10% |
| 70-79 years |
12-18% |
| 80+ years |
15-25% |
- Incidental findings: Most cases are incidental at autopsy
- Clinical correlation: Often no clear antemortem diagnosis
- Comorbidities: Most cases have other pathologies
¶ Management and Care
Clinical workup should include:
- Comprehensive neurological exam: Including cognitive testing
- MRI brain: To rule out other pathologies
- FDG-PET: May show hypometabolism pattern
- CSF analysis: To rule out other causes
While no disease-modifying treatments exist:
- Cognitive enhancers: May provide modest benefit
- Antidepressants: For mood symptoms
- Physical therapy: For gait and balance issues
- Occupational therapy: For daily living assistance
Important aspects of care:
- Education: Understanding the disease course
- Support groups: For caregivers and families
- Advance care planning: Early planning for future needs
- Respite care: To prevent caregiver burnout
Priority areas include:
- Blood-based biomarkers: Highly needed for antemortem diagnosis
- Imaging biomarkers: Astrocyte-specific PET ligands
- CSF biomarkers: Tau species specific to astrocytic pathology
- Combined biomarkers: Panels for improved sensitivity
Key areas for drug development:
- Astrocyte-targeting therapies: Novel approaches
- Anti-propagation strategies: Preventing tau spread to astrocytes
- Tau aggregation inhibitors: Broader application
- Anti-inflammatory agents: Targeting neuroinflammation
Needed developments:
- Longitudinal cohorts: Following ARTAG subjects over time
- Biobanks: Tissue and fluid repositories
- Standardization: Unified diagnostic criteria
- Multi-center collaboration: International efforts
Standardized assessment protocols for ARTAG include:
- Sampling strategy: Minimum of 16 brain regions recommended
- Section preparation: Paraffin-embedded sections, 8-12 μm thickness
- Staining protocols: Standard H&E plus immunohistochemistry
- Quantification methods: Semi-quantitative scoring systems
- Quality control: Inter-rater reliability testing essential
Current diagnostic criteria require:
- Essential features: Tau-positive astrocytic lesions
- Supportive features: 4R tau predominance, typical distribution
- Exclusion criteria: Absence of significant neuronal tau pathology
- Classification: Based on anatomical distribution
The relationship between ARTAG and AD is complex:
- Co-occurrence rate: Up to 30% of AD cases have ARTAG
- Independence: Often considered separate pathological entities
- Additive effects: May contribute to cognitive decline
- TNF-alpha interactions: Shared inflammatory pathways
¶ Lewy Body Disease Comorbidity
- Synucleinopathies: Variable overlap with DLB and PD
- Distribution patterns: Different from pure synucleinopathy
- Clinical impact: May modify disease presentation
- Mechanistic implications: Common cellular pathways
- Cerebral small vessel disease: Common comorbidity
- Microvascular changes: May contribute to astrocyte dysfunction
- White matter changes: Often co-localize with ARTAG
- Clinical interaction: Additive cognitive effects
Advanced imaging techniques for studying ARTAG:
- Quantitative MRI: T1, T2, FLAIR analysis
- Diffusion tensor imaging: White matter integrity assessment
- Susceptibility imaging: Iron deposition detection
- Perfusion imaging: Cerebral blood flow patterns
- Functional connectivity: Network-based approaches
Laboratory approaches include:
- Western blot analysis: Tau isoform detection
- ELISA: Phosphorylated tau quantification
- Mass spectrometry: Proteomic profiling
- Single-cell RNA-seq: Astrocyte transcriptional profiles
- Spatial transcriptomics: Regional gene expression
Investigational models include:
- Cell culture: Primary astrocyte cultures
- Organotypic slices: Brain slice cultures
- iPSC-derived astrocytes: Patient-specific models
- Cerebral organoids: Three-dimensional brain models
- Diagnostic costs: MRI, PET, CSF analysis
- Treatment costs: Symptomatic management
- Care costs: Home care, institutionalization
- Economic burden: Significant but understudied
- Current funding: Limited dedicated funding
- Funding sources: NIH, foundations, industry
- Research gaps: Significant unmet need
- Symptom burden: Variable depending on comorbidities
- Functional impact: Often minimal in pure ARTAG
- Caregiver burden: Generally lower than other tauopathies
- Support needs: Moderate, often related to aging
¶ Advocacy and Awareness
- Patient organizations: Limited specific advocacy
- Awareness: Growing among neurologists and neuropathologists
- Education: Need for healthcare provider education
- Research priorities: Patient-driven priorities emerging
- Population screening: Not currently recommended
- At-risk populations: Older individuals
- Early detection: Limited clinical utility currently
Potential preventive approaches include:
- Lifestyle modifications: Physical activity, cognitive engagement
- Cardiovascular health: Blood pressure, diabetes management
- Trauma prevention: Head injury reduction
- Dietary approaches: Mediterranean diet, antioxidants
While both involve astrocytic tau:
- Distribution differences: PSP shows brainstem predominance
- Morphology: PSP has tufted astrocytes, different from TSA
- Clinical correlates: PSP has characteristic supranuclear gaze palsy
- Genetics: Different MAPT subhaplotype associations
Key distinctions include:
- Anatomical pattern: CBD shows more cortical involvement
- Astrocytic plaques: Characteristic of CBD
- Co-occurring pathologies: CBD often has neuronal loss
- Clinical presentation: CBD has asymmetric onset
Normal aging versus pathological ARTAG:
- Tau in normal aging: Rare neuronal tau, minimal astrocytic
- ARTAG pathology: Significant astrocytic tau accumulation
- Threshold for pathology: Consensus definitions evolving
- Clinical significance: Higher pathology correlates with symptoms
Typical case presentation:
- Patient profile: 78-year-old cognitively normal male
- Clinical course: Died of unrelated cause
- Neuropathology: ARTAG limited to frontal cortex
- Comorbidities: Mild amyloid, no significant vascular disease
- Cognitive status: Normal until death
Common presentation:
- Patient profile: 82-year-old female with dementia
- Clinical course: Progressive memory loss
- Neuropathology: ARTAG plus moderate AD pathology
- Contribution: ARTAG likely additive to cognitive decline
- Diagnosis: Mixed pathology at autopsy
Overlap case:
- Patient profile: 75-year-old male with parkinsonism
- Clinical course: Vertical gaze palsy, falls
- Neuropathology: ARTAG plus PSP changes
- Interpretation: Spectrum of 4R tauopathies
- Implications: Classification challenges
Standard laboratory approach:
- Tissue fixation: 10% neutral buffered formalin
- Antigen retrieval: Heat-induced epitope retrieval
- Primary antibodies: AT8 (1:1000), AT100 (1:500)
- Detection: DAB chromogen system
- Counterstain: Hematoxylin
Recommended brain regions:
- Frontal cortex: Superior frontal gyrus
- Temporal cortex: Inferior temporal gyrus
- Hippocampus: Anterior and posterior
- Basal ganglia: Caudate, putamen
- Brainstem: Substantia nigra, locus coeruleus
- Cerebellum: Dentate nucleus
Semi-quantitative scoring:
- 0: No lesions
- 1: Sparse lesions
- 2: Moderate lesions
- 3: Frequent lesions
- 4: Very frequent lesions
Aging-Related Tau Astrogliopathy (ARTAG) represents an important pathological entity in the aging brain. While often an incidental finding, it may contribute to cognitive decline, particularly when combined with other neurodegenerative pathologies. Understanding ARTAG's relationship to other tauopathies, its clinical impact, and developing biomarkers and treatments remain active areas of research. As the population ages, the significance of ARTAG as both a contributor to age-related cognitive decline and a model for astrocytic involvement in neurodegeneration will likely increase.